PriceSensitive

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

ASX News, Health Care
ASX:EMV      MCAP $131.9M
20 November 2026 12:52 (AEDT)

Traumatic brain injury is one of the leading causes of death and disability worldwide. Source Adobe Stock.

EMVision Medical Devices (ASX: EMV) has been awarded a $3 million grant under round 19 of the Australian government’s national Cooperative Research Centres Projects (CRC-P) program.

The grant will fund the development and preliminary clinical validation of EMVision’s First Responder device for the assessment of suspected traumatic brain injury (TBI), with a central focus on detecting traumatic intracranial haemorrhage (tICH).

This is a new grant, separate from and in addition to the $3 million CRC-P grant awarded in 2025 for the emu regional benefits dtudy.

“A single portable device that can detect a bleed in minutes at the point of care, for both stroke and trauma, and bring treatment and transfer decisions forward to the moment of first contact, is a particularly compelling proposition for patients and healthcare systems,” EMVision CEO and co-founder, Scott Kirkland, said.

“Fresh blood has the same dielectric properties whether it comes from a stroke or a head injury, and as a result, the bleed detection capability we are building into our First Responder for stroke, alongside acute ischaemia detection, gives us a strong foundation for TBI.”

Traumatic brain injury is one of the leading causes of death and disability worldwide, and intracranial haemorrhage is its most time-critical complication.

Mr Kirkland said despite the high incidence and severity of TBI, there is no widely accessible, non-ionising and cost-effective point-of-care neuro-diagnostic tool for rapid TBI assessment.

“Without objective data, diagnostic uncertainty is high at point-of-injury evaluations, leading to suboptimal triage, imperfect evacuation decisions and delayed or incorrect treatment.

“This is especially the case in rural and remote communities, where significant disparities exist in access to TBI care and patient outcomes.

Outside major hospitals, or where symptoms are subtle, patients can wait hours for a CT scan to establish whether a bleed is present. “

Mr Kirkland said a portable First Responder scanner that can identify likely intracranial bleeding at the point of care would allow earlier escalation of patients who may need rapid stabilisation, monitoring and neurosurgical intervention, while avoiding unnecessary transfers for those who do not. The same capability has direct relevance to military, sporting and regional healthcare settings where CT access is delayed or unavailable.

Aged care is a particular focus. Falls are the most common cause of TBI in older people, and residents of aged care homes fall frequently, often while taking blood thinners that increase the risk of a bleed.

EMV was steady at $1.42 with a Mkt cap of $131.9M.

Join the discussion: See what HotCopper users are saying about EMVision Medical Devices and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

Related News